FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158407480> ?p ?o ?g. }

• W2158407480 endingPage "3802" @default.
• W2158407480 startingPage "3792" @default.
• W2158407480 abstract "Abstract Purpose: The purpose of the present study was to evaluate a boronated EGFRvIII-specific monoclonal antibody, L8A4, for boron neutron capture therapy (BNCT) of the receptor-positive rat glioma, F98npEGFRvIII. Experimental Design: A heavily boronated polyamido amine (PAMAM) dendrimer (BD) was chemically linked to L8A4 by two heterobifunctional reagents, N-succinimidyl 3-(2-pyridyldithio)propionate and N-(k-maleimidoundecanoic acid)hydrazide. For in vivo studies, F98 wild-type receptor-negative or EGFRvIII human gene-transfected receptor-positive F98npEGFRvIII glioma cells were implanted i.c. into the brains of Fischer rats. Biodistribution studies were initiated 14 days later. Animals received [125I]BD-L8A4 by either convection enhanced delivery (CED) or direct i.t. injection and were euthanized 6, 12, 24, or 48 hours later. Results: At 6 hours, equivalent amounts of the bioconjugate were detected in receptor-positive and receptor-negative tumors, but by 24 hours the amounts retained by receptor-positive gliomas were 60.1% following CED and 43.7% following i.t. injection compared with 14.6% ID/g by receptor-negative tumors. Boron concentrations in normal brain, blood, liver, kidneys, and spleen all were at nondetectable levels (&lt;0.5 μg/g) at the corresponding times. Based on these favorable biodistribution data, BNCT studies were initiated at the Massachusetts Institute of Technology Research Reactor-II. Rats received BD-L8A4 (∼40 μg 10B/∼750 μg protein) by CED either alone or in combination with i.v. boronophenylalanine (BPA; 500 mg/kg). BNCT was carried out 24 hours after administration of the bioconjugate and 2.5 hours after i.v. injection of BPA for those animals that received both agents. Rats that received BD-L8A4 by CED in combination with i.v. BPA had a mean ± SE survival time of 85.5 ± 15.5 days with 20% long-term survivors (&gt;6 months) and those that received BD-L8A4 alone had a mean ± SE survival time of 70.4 ± 11.1 days with 10% long-term survivors compared with 40.1 ± 2.2 days for i.v. BPA and 30.3 ± 1.6 and 26.3 ± 1.1 days for irradiated and untreated controls, respectively. Conclusions: These data convincingly show the therapeutic efficacy of molecular targeting of EGFRvIII using either boronated monoclonal antibody L8A4 alone or in combination with BPA and should provide a platform for the future development of combinations of high and low molecular weight delivery agents for BNCT of brain tumors." @default.
• W2158407480 created "2016-06-24" @default.
• W2158407480 creator A5004332266 @default.
• W2158407480 creator A5005285266 @default.
• W2158407480 creator A5008787851 @default.
• W2158407480 creator A5011756749 @default.
• W2158407480 creator A5012238012 @default.
• W2158407480 creator A5023164401 @default.
• W2158407480 creator A5023913184 @default.
• W2158407480 creator A5024364711 @default.
• W2158407480 creator A5034088520 @default.
• W2158407480 creator A5036910737 @default.
• W2158407480 creator A5040238670 @default.
• W2158407480 creator A5053202206 @default.
• W2158407480 creator A5053498703 @default.
• W2158407480 creator A5080838490 @default.
• W2158407480 creator A5087233281 @default.
• W2158407480 date "2006-06-15" @default.
• W2158407480 modified "2023-10-05" @default.
• W2158407480 title "Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4" @default.
• W2158407480 cites W1907058105 @default.
• W2158407480 cites W1910586263 @default.
• W2158407480 cites W1966872277 @default.
• W2158407480 cites W1968029748 @default.
• W2158407480 cites W1970941198 @default.
• W2158407480 cites W1978025510 @default.
• W2158407480 cites W1982152660 @default.
• W2158407480 cites W1986702569 @default.
• W2158407480 cites W1987408132 @default.
• W2158407480 cites W1999358182 @default.
• W2158407480 cites W1999963946 @default.
• W2158407480 cites W2012989539 @default.
• W2158407480 cites W2014444830 @default.
• W2158407480 cites W2014500796 @default.
• W2158407480 cites W2017590704 @default.
• W2158407480 cites W2026873511 @default.
• W2158407480 cites W2029315636 @default.
• W2158407480 cites W2033996844 @default.
• W2158407480 cites W2037877043 @default.
• W2158407480 cites W2042183644 @default.
• W2158407480 cites W2044164666 @default.
• W2158407480 cites W2049292021 @default.
• W2158407480 cites W2050756955 @default.
• W2158407480 cites W2054232940 @default.
• W2158407480 cites W2058607011 @default.
• W2158407480 cites W2063349980 @default.
• W2158407480 cites W2063922604 @default.
• W2158407480 cites W2071770777 @default.
• W2158407480 cites W2080096913 @default.
• W2158407480 cites W2084526557 @default.
• W2158407480 cites W2088472732 @default.
• W2158407480 cites W2097670451 @default.
• W2158407480 cites W2102691127 @default.
• W2158407480 cites W2103875971 @default.
• W2158407480 cites W2132305988 @default.
• W2158407480 cites W2133520325 @default.
• W2158407480 cites W2133835288 @default.
• W2158407480 cites W2135881288 @default.
• W2158407480 cites W2142564546 @default.
• W2158407480 cites W2145030327 @default.
• W2158407480 cites W2147019056 @default.
• W2158407480 cites W2156071539 @default.
• W2158407480 cites W2158969219 @default.
• W2158407480 cites W2161710468 @default.
• W2158407480 cites W2165757582 @default.
• W2158407480 cites W2178389534 @default.
• W2158407480 cites W4214512856 @default.
• W2158407480 cites W4249145723 @default.
• W2158407480 cites W4250830968 @default.
• W2158407480 cites W78748194 @default.
• W2158407480 doi "https://doi.org/10.1158/1078-0432.ccr-06-0141" @default.
• W2158407480 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16778107" @default.
• W2158407480 hasPublicationYear "2006" @default.
• W2158407480 type Work @default.
• W2158407480 sameAs 2158407480 @default.
• W2158407480 citedByCount "87" @default.
• W2158407480 countsByYear W21584074802012 @default.
• W2158407480 countsByYear W21584074802013 @default.
• W2158407480 countsByYear W21584074802014 @default.
• W2158407480 countsByYear W21584074802015 @default.
• W2158407480 countsByYear W21584074802016 @default.
• W2158407480 countsByYear W21584074802017 @default.
• W2158407480 countsByYear W21584074802018 @default.
• W2158407480 countsByYear W21584074802019 @default.
• W2158407480 countsByYear W21584074802020 @default.
• W2158407480 countsByYear W21584074802021 @default.
• W2158407480 countsByYear W21584074802022 @default.
• W2158407480 countsByYear W21584074802023 @default.
• W2158407480 crossrefType "journal-article" @default.
• W2158407480 hasAuthorship W2158407480A5004332266 @default.
• W2158407480 hasAuthorship W2158407480A5005285266 @default.
• W2158407480 hasAuthorship W2158407480A5008787851 @default.
• W2158407480 hasAuthorship W2158407480A5011756749 @default.
• W2158407480 hasAuthorship W2158407480A5012238012 @default.
• W2158407480 hasAuthorship W2158407480A5023164401 @default.
• W2158407480 hasAuthorship W2158407480A5023913184 @default.
• W2158407480 hasAuthorship W2158407480A5024364711 @default.
• W2158407480 hasAuthorship W2158407480A5034088520 @default.

• next